GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (OTCPK:RKVTF) » Definitions » Land And Improvements

RKVTF (Rakovina Therapeutics) Land And Improvements : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Rakovina Therapeutics Land And Improvements?

Rakovina Therapeutics's land and improvements for the quarter that ended in Mar. 2025 was $0.00 Mil.


Rakovina Therapeutics Land And Improvements Historical Data

The historical data trend for Rakovina Therapeutics's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Land And Improvements Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Land And Improvements
- - - -

Rakovina Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Rakovina Therapeutics Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


Rakovina Therapeutics Business Description

Traded in Other Exchanges
Address
105 1008 Beach Avenue, Vancouver, BC, CAN, V6E 1T7
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a much greater pace than ever before. The company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.